Patents Represented by Attorney Stephen C. D'Amico
  • Patent number: 8150634
    Abstract: A method of enhancing the throughput and applicability of NMR-based structure determination of protein-ligand complexes is disclosed. The method circumvents the need for protein sequence-specific resonance assignments and combines NMR data analysis and ligand docking methods into an integrated process. In one embodiment, NMR data is used to filter docking results to identify the most consistent binding modes, thereby providing structural information in a high-throughput fashion without the need for assigning protein resonances. Trial assignments for protein-ligand nuclear Overhauser effect (NOE) interactions are also produced by the method.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: April 3, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Keith Lewis Constantine, Brian Lee Claus, Malcolm Evan Davis, William Joseph Metzler, Luciano Mueller
  • Patent number: 8129114
    Abstract: EGFR biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker selected from epiregulin and amphiregulin, (b) exposing a biological sample from the mammal to the EGFR modulator, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: March 6, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shirin K. Ford, Edwin A. Clark, Xin Huang
  • Patent number: 8124729
    Abstract: The present invention provides novel polynucleotides encoding HGPRBMY28 and HGPRBMY29 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding splice variants of HGPRBMY29 polypeptides, HGPRBMY29v1 and HGPRBMY29v2. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HGPRBMY28, HGPRBMY29, HGPRBMY29v1, and HGPRBMY29v2 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: February 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Chandra S. Ramanathan, Gabriel A. Mintier, David K. Bol, Donald R. Hawken
  • Patent number: 8124730
    Abstract: The present invention provides novel polynucleotides encoding HBMYP2X7v polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel HBMYP2X7v polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: September 4, 2007
    Date of Patent: February 28, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Diana L. Franco, Chandra S. Ramanathan, Martin A. Lewis
  • Patent number: 8119129
    Abstract: Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: February 21, 2012
    Assignee: Bristol-Myers Squibb Company
    Inventors: Maria Jure-Kunkel, Francis Y. Lee
  • Patent number: 8080636
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: December 20, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
  • Patent number: 7851190
    Abstract: Polypeptides and domains of leptomycin polyketide synthase and the nucleic acids encoding them are provided. Methods to prepare leptomycin, leptomycin analogs, and leptomycin derivatives are described, as are methods to prepare other polyketides using the nucleic acids encoding leptomycin polyketide synthase domains or modifying enzymes.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: December 14, 2010
    Assignee: Kosan Biosciences, Inc.
    Inventors: Zhihao Hu, Ralph C. Reid
  • Patent number: 7846671
    Abstract: The present invention provides methods that are useful for the treatment or prevention of smooth muscle disorders such as urinary incontinence and compounds that are useful in such methods.
    Type: Grant
    Filed: January 27, 2003
    Date of Patent: December 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark Cockett, Chandra S. Ramanathan, Nicholas J. Lodge, Kevin Fitzgerald, Terry Stouch, Lisa Moore, Rachel M. Kindt, Jenny Kopczynski, Stephen Kohl Doberstein
  • Patent number: 7811787
    Abstract: The invention relates to the identification and cloning of a two novel full-length human SLAP-2 variants and their encoded polypeptides, hSLAP-2v3 and hSLAP-2v4. hSLAP-2v3 and hSLAP-2v4 are members of the SLAP family of adapter proteins and are involved in the negative regulation of intracellular T-cell signal transduction. The invention further relates to the use of these novel hSLAP-2v3 and hSLAP-2v4 polynucleotides and their encoded polypeptides as targets for therapeutic intervention in immunological and inflammatory disorders, autoimmune diseases, pulmonary diseases, proliferative immune disorders, and cancer.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: October 12, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Donald G. Jackson, Stanley R. Krystek, Jr., Donna A. Bassolino, Rolf-Peter Ryseck, Thomas C. Nelson, Gena S. Whitney
  • Patent number: 7807786
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: October 5, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Glen Eugene Mikesell, Han Chang, Robert James Peach
  • Patent number: 7790428
    Abstract: The present invention provides essential fungal polynucleotides and their encoded polypeptides, homologues thereof and their uses. Additionally, the invention provides methods for the identification of essential polynucleotides and fungal strains which may be used for drug screening.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: September 7, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ying-Kai Wang, Mengping Liu, Brian A. Dougherty, Matthew D. Healy, Daniel B. Davison, Charles E. Mazzucco, Trina Maurice
  • Patent number: 7767418
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of LTRPC3 polypeptides, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f, respectively. Also provided are vectors, host cells, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3, LTRPC3b, LTRPC3c, LTRPC3d, LTRPC3e, and LTRPC3f polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: May 15, 2008
    Date of Patent: August 3, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ning Lee, Jian Chen, John N. Feder, Shujian Wu, Liana M. Lee, Michael A. Blanar
  • Patent number: 7741025
    Abstract: The present invention provides novel polynucleotides encoding BGS-42 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-42 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: September 10, 2007
    Date of Patent: June 22, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: John N. Feder, Shujian Wu, Thomas C. Nelson, Liana M. Lee
  • Patent number: 7723479
    Abstract: The present invention provides nucleic acids encoding B7-related factors that modulate the activation of immune or inflammatory response cells, such as T-cells. Also provided are expression vectors and fusion constructs comprising nucleic acids encoding B7-related polypeptides, including BSL1, BSL2, and BSL3. The present invention further provides isolated B7-related polypeptides, isolated fusion proteins comprising B7-related polypeptides, and antibodies that are specifically reactive with B7-related polypeptides, or portions thereof. In addition, the present invention provides assays utilizing B7-related nucleic acids, polypeptides, or peptides. The present invention further provides compositions of B7-related nucleic acids, polypeptides, fusion proteins, or antibodies that are useful for the immunomodulation of a human or animal subject.
    Type: Grant
    Filed: September 6, 2007
    Date of Patent: May 25, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Glen Eugene Mikesell, Han Chang, Joshua N. Finger, Guchen Yang, Robert James Peach, Henry Shen
  • Patent number: 7714118
    Abstract: Host cells comprising recombinant vectors encoding the FK-520 polyketide synthase and FK-520 modification enzymes can be used to produce the FK-520 polyketide. Recombinant DNA constructs comprising one or more FK-520 polyketide synthase domains, modules, open reading frames, and variants thereof can be used to produce recombinant polyketide synthases and a variety of different polyketides with application as pharmaceutical and veterinary products.
    Type: Grant
    Filed: July 6, 2004
    Date of Patent: May 11, 2010
    Assignee: Kosan Biosciences Incorporated
    Inventors: Christopher Reeves, Kai Wu
  • Patent number: 7705133
    Abstract: The present invention provides novel polynucleotides encoding LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel LTRPC3g, LTRPC3h, LTRPC3i, LTRPC3j, LTRPC3k, or LTRPC3l polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: July 22, 2008
    Date of Patent: April 27, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ning Lee, Jian Chen, Shujian Wu, Michael A. Blanar, Paul C. Levesque, Lucy Sun
  • Patent number: 7680601
    Abstract: Methods for the computational analysis of polyketides and the computer-assisted design of PKS genes are facilitated by representing the structure of a polyketide and/or a PKS gene that encodes the PKS that produces the polyketide by alphanumeric symbols that facilitates computer assisted analysis. A database of polyketides and corresponding PKS genes that can be rapidly searched and information extracted for a variety of applications, including the design and specification of PKS genes via the recombining of modules or portions of modules or sets of modules from already known and available PKS genes.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: March 16, 2010
    Assignee: Kosan Biosciences
    Inventors: Chaitan Khosla, Ralph C. Reid, Daniel V. Santi, Michael A. Siani
  • Patent number: 7671190
    Abstract: The invention relates to recombinant polyketide synthase enzymes, polyketide modifying proteins, and other proteins involved in polyketide biosynthesis or function. The invention provides domains of geldanamycin and herbimycin polyketide synthases, polynucleotides that encode such enzymes, and to host cells in which such encoding polynucleotides can be advantageously expressed.
    Type: Grant
    Filed: January 16, 2007
    Date of Patent: March 2, 2010
    Assignee: Kosan Biosciences Incorporation
    Inventors: Richard C. Hutchinson, Ralph C. Reid, Zhihao Hu, Andreas Rascher, Andreas Schirmer, Robert McDaniel
  • Patent number: 7667003
    Abstract: The present invention describes a newly discovered full-length polynucleotide encoding an SH2 domain-containing adapter protein, called human MIST, cloned, isolated and identified from a human spleen cDNA library. Also described are the MIST polypeptide sequence, expression vectors, host cells, agonists, antagonists, antisense molecules, and antibodies related to the polynucleotide and/or polypeptide of the present invention. Novel splice variant forms of human MIST are provided. Methods for screening for modulators, particularly inhibitors, of the MIST protein and use of the human MIST polynucleotide and polypeptide for therapeutics and diagnostics are described.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: February 23, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Juan J. Perez-Villar, Han Chang, Steven B. Kanner, Gena S. Whitney, Yuli Wu, Wen-Pin Yang
  • Patent number: 7642049
    Abstract: The invention provides a novel in vitro method for identifying HIV-1 protease inhibitors with reduced potential for inducing metabolic abnormalities. The invention further provides diagnostic methods for identifying patients who may be at risk of developing metabolic abnormalities subsequent to the administration of an HIV-1 protease inhibitor. The invention also provides novel polynucleotides associated with the incidence of HIV-1 protease inhibitor induced metabolic abnormalities. The invention also provides polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides which comprise at least one polymorphic locus per fragment. Allele-specific primers and probes which hybridize to these regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: January 5, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventor: Koustubh Ranade